These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 2054231)

  • 1. Effects of amino-butylidene diphosphonate in hypercalcemia due to malignancy.
    Bickerstaff DR; O'Doherty DP; McCloskey EV; Hamdy NA; Mian M; Kanis JA
    Bone; 1991; 12(1):17-20. PubMed ID: 2054231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate.
    Jacobs TP; Siris ES; Bilezikian JP; Baquiran DC; Shane E; Canfield RE
    Ann Intern Med; 1981 Mar; 94(3):312-6. PubMed ID: 6452846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate.
    Shane E; Jacobs TP; Siris ES; Steinberg SF; Stoddart K; Canfield RE; Bilezikian JP
    Am J Med; 1982 Jun; 72(6):939-44. PubMed ID: 6211978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of hypercalcemia in osteolytic metastases with oral amino-hydroxypropylidene-diphosphonate].
    Tubiana-Hulin M; de Vernejoul MC; Brière M; Miravet L; Clavel B
    Presse Med; 1984 Feb; 13(8):483-6. PubMed ID: 6230630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
    Zysset E; Ammann P; Jenzer A; Gertz BJ; Portmann L; Rizzoli R; Jaquet-Müller F; Pryor-Tillotson S; Bonjour JP; Burckhardt P
    Bone Miner; 1992 Sep; 18(3):237-49. PubMed ID: 1392697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of the hypercalcaemia of malignancy with intravenous clodronate.
    Urwin GH; Yates AJ; Gray RE; Hamdy NA; McCloskey EV; Preston FE; Greaves M; Neil FE; Kanis JA
    Bone; 1987; 8 Suppl 1():S43-51. PubMed ID: 2961354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease.
    Douglas DL; Duckworth T; Russell RG; Kanis JA; Preston CJ; Preston FE; Prenton MA; Woodhead JS
    Lancet; 1980 May; 1(8177):1043-7. PubMed ID: 6103389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia.
    Wüster C; Schöter KH; Thiébaud D; Manegold C; Krahl D; Clemens MR; Ghielmini M; Jaeger P; Scharla SH
    Bone Miner; 1993 Aug; 22(2):77-85. PubMed ID: 8251767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dichloromethylene diphosphonate action in hematologic and other malignancies.
    Canfield RE; Siris ES; Jacobs TP
    Bone; 1987; 8 Suppl 1():S57-62. PubMed ID: 2961356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
    Body JJ; Borkowski A; Cleeren A; Bijvoet OL
    J Clin Oncol; 1986 Aug; 4(8):1177-83. PubMed ID: 3016205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cancer associated hypercalcaemia with combined aminohydroxypropylidene diphosphonate and calcitonin.
    Ralston SH; Alzaid AA; Gardner MD; Boyle IT
    Br Med J (Clin Res Ed); 1986 Jun; 292(6535):1549-50. PubMed ID: 3087513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
    van Breukelen FJ; Bijvoet OL; van Oosterom AT
    Lancet; 1979 Apr; 1(8120):803-5. PubMed ID: 86043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy of malignancy-associated hypercalcemia: 1983.
    Stewart AF
    Am J Med; 1983 Mar; 74(3):475-80. PubMed ID: 6219580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP.
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    J Clin Oncol; 1988 May; 6(5):762-8. PubMed ID: 3367184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic lymphocytic leukemia and hypercalcemia: treatment with dichloromethylene diphosphonate.
    Siris ES; Grossbard L; Halper JP; Blume RS; Jacobs TP
    Metab Bone Dis Relat Res; 1983-1984; 5(2):61-3. PubMed ID: 6231452
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
    Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
    J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of hypercalcemia of myelomatous origin with intravenous diphosphonates].
    Charhon S; Chapuy MC; Valentin-Opran A; Edouard C; Rosini S; Meunier PJ
    Presse Med; 1983 Dec; 12(47):2983-6. PubMed ID: 6228888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of neoplastic hypercalcemia using single-infusion diphosphonate].
    Thiébaud D; Jaeger P; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1988 Jan; 118(3):77-81. PubMed ID: 3344411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton.
    Siris ES; Hyman GA; Canfield RE
    Am J Med; 1983 Mar; 74(3):401-6. PubMed ID: 6219577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of aminohydroxypropylidene diphosphonate, mithramycin, and corticosteroids/calcitonin in treatment of cancer-associated hypercalcaemia.
    Ralston SH; Gardner MD; Dryburgh FJ; Jenkins AS; Cowan RA; Boyle IT
    Lancet; 1985 Oct; 2(8461):907-10. PubMed ID: 2865417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.